In order to compare the enteric circulation of estriol-16α-glucosiduronate (see preceding paper) with that of estriol (E3), labeled estriol was administered to six women by several routes: both injection and infusion (300 min) into the cubital vein, injection into the portal vein system, ingestion and instillation into the jejunum and ileum. Urine, collected from 0-2, 2-4, 4-8, 8-12, and 12-24 hr, was analyzed by countercurrent distribution for its content of radioactive 3- and 16-glucosiduronate (E3-3Gl,E3-16Gl) and sulfoglucosiduronate (E3-3S,16Gl) of estriol. After peripheral injection of E3, E3-16Gl was excreted rapidly and E3-3S,16Gl at a slower and more constant rate. E3-3Gl was barely detectable after infusion. After injection of E3 into the portal vein, the excretion of E3-3S,16Gl was greater and quicker than after peripheral injection. Even in a subject with a complete bile fistula, the urinary excretion of E3-3S,16Gl was essentially unchanged. Ingestion also produced the same result. Only after instillation into the ileum was a large and rapid excretion of E3-3Gl obtained, whereas the excretion of E3-3S,16Gl, and E3-16Gl were depressed. These results together with those of the preceding paper suggest that E3 does not readily appear in the small intestine except via a hepatoenteric circulation that produces very little E3-3Gl. When present in the distal segment of the small intestine, however, absorption, conjugation, and elimination proceed readily.
N. Inoue, A. A. Sandberg, J. B. Graham, W. R. Slaunwhite Jr.
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.